(RTTNews) - PUMA SE (PUM.DE), on Thursday, announced that Chief Financial Officer Markus Neubrand will step down from his role effective April 30 and appointed Mark Langer as CFO and Member of the Management Board, effective May 1.
(RTTNews) - PUMA SE (PUM.DE), on Thursday, announced that Chief Financial Officer Markus Neubrand will step down from his role effective April 30 and appointed Mark Langer as CFO and Member of the Management Board, effective May 1.
Palantir Technologies (NASDAQ: PLTR) is one of the biggest names in the artificial intelligence (AI) software space. The company's Artificial Intelligence Platform (AIP) has been quite popular among customers looking to integrate generative AI tools into their business operations. The success of Palantir's AIP has supercharged the stock over the past three years, leading to phenomenal gains of 1,7...
Palantir Technologies (NASDAQ: PLTR) is one of the biggest names in the artificial intelligence (AI) software space. The company's Artificial Intelligence Platform (AIP) has been quite popular among customers looking to integrate generative AI tools into their business operations. The success of Palantir's AIP has supercharged the stock over the past three years, leading to phenomenal gains of 1,730%. However, the remarkable rally in Palantir stock has made it very expensive. Though Palantir could justify its valuation by sustaining outstanding earnings growth over the long run, conservative investors may want to look elsewhere to capitalize on the fast-growing AI software market. Snowflake (NYSE: SNOW) is one such AI stock that can help investors capitalize on this lucrative niche, and at a significantly lower valuation than Palantir. Let's see why Snowflake could be one of the best AI software stocks to buy and hold for the next decade. Continue reading
SK hynix (KOSE:A000660) has started mass production of 192GB SOCAMM2 memory modules for AI servers. The new modules are designed for NVIDIA's latest platform and tuned for large language model workloads. The product targets memory capacity and efficiency constraints in high performance AI computing. SK hynix is a major memory supplier to global data center and AI customers, and the move into mass ...
SK hynix (KOSE:A000660) has started mass production of 192GB SOCAMM2 memory modules for AI servers. The new modules are designed for NVIDIA's latest platform and tuned for large language model workloads. The product targets memory capacity and efficiency constraints in high performance AI computing. SK hynix is a major memory supplier to global data center and AI customers, and the move into mass production of SOCAMM2 modules ties directly into rising demand for AI server hardware. By...
AlexSecret Defense supplier L3Harris ( LHX ) on Wednesday said that it has confidentially submitted a draft registration statement for the initial public offering of its missile solutions business. The company said the number of shares to be offered and the price range for the proposed IPO are yet to be determined. In January, L3Harris said it plans to sell new equity in its growing rocket m...
AlexSecret Defense supplier L3Harris ( LHX ) on Wednesday said that it has confidentially submitted a draft registration statement for the initial public offering of its missile solutions business. The company said the number of shares to be offered and the price range for the proposed IPO are yet to be determined. In January, L3Harris said it plans to sell new equity in its growing rocket motor business, creating a new company backed by a $1B U.S. government convertible security investment. The stock has risen about 10% YTD. More on L3Harris Technologies L3Harris: Strong Results Coming, But A Weak Stock For The Near Term L3Harris: The Pentagon Buys, Wall Street Follows L3Harris Technologies, Inc. (LHX) Presents at JPMorgan Industrials Conference 2026 Transcript L3Harris Technologies Q1 2026 Earnings Preview L3Harris wins $65M rocket motor contract for tactical missiles
Earnings Call Insights: Viking Therapeutics (VKTX) Q1 2026 Management View Brian Lian said the quarter’s operational focus was advancing VK2735 across multiple Phase III-enabling paths, stating, "we made significant progress with our obesity franchise, highlighted by our lead compound, VK2735" and adding that "we were pleased to announce the completion of enrollment in the VANQUISH-2 trial. Both s...
Earnings Call Insights: Viking Therapeutics (VKTX) Q1 2026 Management View Brian Lian said the quarter’s operational focus was advancing VK2735 across multiple Phase III-enabling paths, stating, "we made significant progress with our obesity franchise, highlighted by our lead compound, VK2735" and adding that "we were pleased to announce the completion of enrollment in the VANQUISH-2 trial. Both studies continue to proceed on track." Lian highlighted a key development change for the oral program, saying, "based on the positive top line results reported in our Phase II VENTURE-Oral dosing study, the company elected to advance oral VK2735 into Phase III clinical development" and specifying, "We currently expect to initiate this program in the fourth quarter of this year." Lian emphasized optionality and administration upgrades inside Phase III, stating, "participants in both VANQUISH studies began transitioning to the auto-injector device" and adding, "This transition has been proceeding smoothly." Gregory Zante quantified the step-up in investment, saying, "Research and development expenses were $150.2 million for the 3 months ended March 31, 2026" and "General and administrative expenses were $14 million." Zante summarized profitability and liquidity, stating, "For the 3 months ended March 31, 2026, Viking recorded a net loss of $158.3 million or $1.37 per share" and "At March 31, 2026, Viking held cash, cash equivalents and short-term investments of $603 million." Lian framed the commercialization build-out around a new executive hire, stating, "the company announced in the first quarter the appointment of Neil Aubuchon as its first Chief Commercial Officer" and adding, "We are excited to have him on board to lead this critical operation." Outlook Lian guided to multiple clinical catalysts, saying, "We expect to report the results of this study in the third quarter" (maintenance dosing study) and "Pending clearance, we expect to initiate a Phase I clinical trial fo...